AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31511278 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 1490
Study 28705248 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% imidacloprid/4.5% flumethrin polymer matrix collar (G1)
Number of subjects: 204
Study 28705248 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (G2)
Number of subjects: 204
Study 25681068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin 1000 mg intravenous (i.v.)
Number of subjects: 200
Study 25681068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin 1500 mg intravenous (i.v.)
Number of subjects: 200
Study 25681068 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenous (i.v.)
Number of subjects: 200
Study 25681068 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg oral
Number of subjects: 200
Study 23412942 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-month duration)
Number of subjects: 179
Study 23412942 — intervention group
Group type: COMPARATOR
Intervention: Dropouts
Number of subjects: 179
Study 23412942 — intervention group
Group type: COMPARATOR
Intervention: Completers
Number of subjects: 179
Study 21733508 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus combined hormonal oral contraceptive (OC)
Number of subjects: 19
Study 21733508 — intervention group
Group type: COMPARATOR
Intervention: OC plus matched placebo
Number of subjects: 19
Study 19910719 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 19910719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16731290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 1094
Study 16731290 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 1094
Study 16731290 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1094
Study 16731290 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure control
Number of subjects: 1094
Study 16731290 — intervention group
Group type: COMPARATOR
Intervention: Low blood pressure control
Number of subjects: 1094
Study 14609531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract (Zintona EC) 250 mg of Zingiberis Rhizoma per capsule, qid
Number of subjects: 29
Study 14609531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical looking capsules)
Number of subjects: 29
Study 14609531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract (Zintona EC)
Number of subjects: 29
Study 14609531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10824663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS) patients
Number of subjects: 65
Study 10824663 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD) patients
Number of subjects: 65
Study 10824663 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study 8876341 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine-glucose mixture
Number of subjects: 18
Study 8876341 — intervention group
Group type: COMPARATOR
Intervention: Glucose powder (placebo)
Number of subjects: 18
Study 1857251 — intervention group
Group type: EXPERIMENTAL
Intervention: Icons
Number of subjects: 0
Study 1857251 — intervention group
Group type: COMPARATOR
Intervention: Narrative text, table, pie chart
Number of subjects: 0
Study 6574531 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 6574531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3963032 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 19
Study 3963032 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 19
Study 3963032 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 19
Study 3963032 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 19
Study 3963032 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 20 mg
Number of subjects: 19
Study 3963032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3963032 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (all doses)
Number of subjects: 19
Study 3963032 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone and Diazepam
Number of subjects: 19
Study 29325064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 40
Study 29325064 — intervention group
Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 40
Study 27281061 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 262
Study 27281061 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 262
Study 24884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training and muscle strengthening (12 sessions to strengthen knee extensors, hip abductors, and lateral rotators)
Number of subjects: 34
Study 24884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training and muscle strengthening
Number of subjects: 34
Study 24884455 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 sessions to strengthen hip and knee muscles)
Number of subjects: 34
Study 24884455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 22240397 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant ApfA alone
Number of subjects: 0
Study 22240397 — intervention group
Group type: COMPARATOR
Intervention: rApxIVA or rTbpB alone
Number of subjects: 0
Study 22240397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri‐antigen combination of rApxIA, rApxIIA and rApxIIIA
Number of subjects: 0
Study 22240397 — intervention group
Group type: COMPARATOR
Intervention: Penta‐antigen mixture of rApxIA, rApxIIA, rApxIIIA, rApxIVA and rTbpB
Number of subjects: 0
Study 22240397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexa‐antigen vaccine containing rApfA
Number of subjects: 0
Study 22240397 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with rApfA alone or in combination with other antigens
Number of subjects: 0
Study 20175977 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol/acetaminophen 37.5 mg/325 mg
Number of subjects: 22
Study 20175977 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg bid
Number of subjects: 22
Study 20175977 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 18771003 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg
Number of subjects: 0
Study 18771003 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg
Number of subjects: 0
Study 18771003 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg, q.d. (multiple doses)
Number of subjects: 0
Study 15976587 — intervention group
Group type: EXPERIMENTAL
Intervention: Microchannel lens (MC)
Number of subjects: 15
Study 15976587 — intervention group
Group type: COMPARATOR
Intervention: Standard hydrogel lens design (STD)
Number of subjects: 15
Study 15976587 — intervention group
Group type: EXPERIMENTAL
Intervention: Microchannel lens (MC) and Standard hydrogel lens design (STD)
Number of subjects: 15
Study 12524662 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement for 8 weeks
Number of subjects: 0
Study 12524662 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement for 40 weeks
Number of subjects: 0
Study 10783995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine (500 mg/kg body weight/120 min)
Number of subjects: 12
Study 10783995 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 9031710 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Pattern Training (BPT)
Number of subjects: 20
Study 9031710 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional rehabilitation program only)
Number of subjects: 20
Study 10146939 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11
Study 10146939 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11
Study 10146939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine slow release (SR)
Number of subjects: 11
Study 10146939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (GITS)
Number of subjects: 11
Study 10146939 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 6835887 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 8
Study 6835887 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 2 mg
Number of subjects: 8
Study 6835887 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine 1.6 mg
Number of subjects: 8
Study 6835887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30688135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 10 mg/kg/d
Number of subjects: 295
Study 30688135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 2.5 mg/kg/d
Number of subjects: 295
Study 30688135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 29859628 — intervention group
Group type: EXPERIMENTAL
Intervention: Training box games
Number of subjects: 3
Study 29859628 — intervention group
Group type: EXPERIMENTAL
Intervention: Naked-eye box trainer
Number of subjects: 3
Study 29859628 — intervention group
Group type: COMPARATOR
Intervention: Conventional video-based box trainer
Number of subjects: 3
Study 29859628 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study 27665522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin
Number of subjects: 1959
Study 27665522 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1959
Study 24849794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation with physical training
Number of subjects: 16
Study 24849794 — intervention group
Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 16
Study 24849794 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation alone
Number of subjects: 16
Study 22047669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy Competence Scale for Social Phobia (CTCS-SP)
Number of subjects: 98
Study 20578869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin cup with 600 g of force per side (Group 1, n = 20)
Number of subjects: 50
Study 20578869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin cup with 300 g of force per side (Group 2, n = 20)
Number of subjects: 50
Study 20578869 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 3, n = 10)
Number of subjects: 50
Study 18635157 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain activation during Stroop task
Number of subjects: 20
Study 15699762 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (3 g/day, n=36)
Number of subjects: 83
Study 15699762 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir (8 g/day, n=35)
Number of subjects: 83
Study 15699762 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy (n=12)
Number of subjects: 83
Study 11909906 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb function training
Number of subjects: 101
Study 11909906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb function training
Number of subjects: 101
Study 11909906 — intervention group
Group type: COMPARATOR
Intervention: Control group (immobilisation with an inflatable pressure splint)
Number of subjects: 101
Study 11909906 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) scores
Number of subjects: 101
Study 11909906 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb function
Number of subjects: 101
Study 11909906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb function
Number of subjects: 101
Study 10671599 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital radiography with a 4 million-pixel CCD
Number of subjects: 225
Study 10671599 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 225
Study 8650274 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-degree starting angle at a stretch speed of approximately 1.0 radian/s
Number of subjects: 5
Study 8650274 — intervention group
Group type: COMPARATOR
Intervention: Various starting angles and stretch speeds
Number of subjects: 5
Study 2005231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 10
Study 2005231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 10
Study 2005231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthwash
Number of subjects: 10
Study 2005231 — intervention group
Group type: EXPERIMENTAL
Intervention: reformulated 0.1% chlorhexidine mouthwash (not commercially available)
Number of subjects: 10
Study 2005231 — intervention group
Group type: COMPARATOR
Intervention: saline rinse
Number of subjects: 10
Study 6592201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.243% NaF dentifrice
Number of subjects: 0
Study 6592201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 dentifrice
Number of subjects: 0
Study 6592201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30578888 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocked nylon swabs
Number of subjects: 20
Study 30578888 — intervention group
Group type: COMPARATOR
Intervention: Rayon swabs
Number of subjects: 20
Study 29910030 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily added to ezetimibe 10 mg/day for 12 weeks
Number of subjects: 269
Study 29910030 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ezetimibe 10 mg/day for 12 weeks
Number of subjects: 269
Study 26458146 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan + Probucol
Number of subjects: 160
Study 26458146 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 160
Study 23623278 — intervention group
Group type: COMPARATOR
Intervention: 2-stage method (Group A)
Number of subjects: 117
Study 23623278 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-stage method (Group B)
Number of subjects: 117
Study 23623278 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill retention assessment
Number of subjects: 117
Study 22866693 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally accommodated cognitive-behavioral treatment (A-CBT)
Number of subjects: 35
Study 22866693 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behavioral treatment (S-CBT)
Number of subjects: 35
Study 22866693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both A-CBT and S-CBT
Number of subjects: 35
Study 20551457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection
Number of subjects: 67
Study 20551457 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker treatment
Number of subjects: 67
Study 18818551 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple auripuncture plus aspiration
Number of subjects: 96
Study 18818551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic membrane fenestration with cauterization
Number of subjects: 96
Study 18818551 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy plus grommet insertion
Number of subjects: 96
Study 16418553 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean traditional dance movement program (12 weeks, 3 times a week)
Number of subjects: 253
Study 11895169 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures (four skinfolds)
Number of subjects: 2286
Study 11895169 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 2286
Study 11895169 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) and anthropometric measures
Number of subjects: 2286
Study 9926182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow circle anaesthesia (LFA)
Number of subjects: 60
Study 9926182 — intervention group
Group type: COMPARATOR
Intervention: High-flow circle anaesthesia (HFA)
Number of subjects: 60
Study 8672391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1
Number of subjects: 1770
Study 8672391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2
Number of subjects: 1770
Study 8672391 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1770
Study 2221276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal with imagined consequences (C)
Number of subjects: 48
Study 2221276 — intervention group
Group type: COMPARATOR
Intervention: Mental rehearsal with no imagined consequences (N)
Number of subjects: 48
Study 2221276 — intervention group
Group type: COMPARATOR
Intervention: Rest (R)
Number of subjects: 48
Study 863552 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced model
Number of subjects: 117
Study 863552 — intervention group
Group type: COMPARATOR
Intervention: Punished model
Number of subjects: 117
Study 863552 — intervention group
Group type: COMPARATOR
Intervention: Non-facilitative information
Number of subjects: 117
Study 863552 — intervention group
Group type: COMPARATOR
Intervention: Unrelated information
Number of subjects: 117
Study 863552 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitative information
Number of subjects: 117
Study 31050034 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=36, 3 times a week for 1 hour)
Number of subjects: 74
Study 31050034 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 74
Study 28303530 — intervention group
Group type: EXPERIMENTAL
Intervention: BTH1677 (4 mg/kg, weekly) + cetuximab (initial dose 400 mg/m2, subsequent doses 250 mg/m2, weekly) + carboplatin (6 mg/mL/min AUC, Q3W) + paclitaxel (200 mg/m2, Q3W)
Number of subjects: 90
Study 28303530 — intervention group
Group type: COMPARATOR
Intervention: cetuximab + carboplatin + paclitaxel (Control)
Number of subjects: 90
Study 25601916 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g acetyl-l-carnitine for 12 weeks
Number of subjects: 72
Study 25601916 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 72
Study 23020996 — intervention group
Group type: EXPERIMENTAL
Intervention: Long GnRH agonist protocol (group I)
Number of subjects: 330
Study 23020996 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol (group II)
Number of subjects: 330
Study 20543747 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO drink (2:1 glucose-fructose blend; 1.5 g·min)
Number of subjects: 8
Study 20543747 — intervention group
Group type: COMPARATOR
Intervention: Plain water (WAT; 675 mL·h)
Number of subjects: 8
Study 20543747 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (RUN)
Number of subjects: 8
Study 20543747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (CYCLE)
Number of subjects: 8
Study 18301402 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 130
Study 18301402 — intervention group
Group type: COMPARATOR
Intervention: Conventional (Con)
Number of subjects: 130
Study 16749290 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) directed to the infarct-related artery (culprit vessel)
Number of subjects: 0
Study 16749290 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0
Study 16749290 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged revascularization strategy
Number of subjects: 0
Study 14657964 — intervention group
Group type: EXPERIMENTAL
Intervention: GP recruitment strategies including early consultation with GPs, benefits for participating GPs and patients, and a comprehensive suburb‐by‐suburb approach.
Number of subjects: 327
Study 14657964 — intervention group
Group type: EXPERIMENTAL
Intervention: Referring GPs' attitudes towards participation in research.
Number of subjects: 327
Study 14657964 — intervention group
Group type: COMPARATOR
Intervention: Comparison between referring and non-referring GPs.
Number of subjects: 327
Study 10982049 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) anal plug
Number of subjects: 38
Study 10982049 — intervention group
Group type: COMPARATOR
Intervention: PVA anal plug
Number of subjects: 38
Study 10982049 — intervention group
Group type: EXPERIMENTAL
Intervention: Both plugs
Number of subjects: 38
Study 9250837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists evaluating porcelain, direct resin composite, and indirect resin composite VRs
Number of subjects: 112
Study 9250837 — intervention group
Group type: EXPERIMENTAL
Intervention: Beautician students evaluating porcelain, direct resin composite, and indirect resin composite VRs
Number of subjects: 112
Study 9250837 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of VRs made in one patient
Number of subjects: 112
Study 9250837 — intervention group
Group type: EXPERIMENTAL
Intervention: Discolouration of the teeth before treatment
Number of subjects: 112
Study 9250837 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of VR
Number of subjects: 112
Study 9250837 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of VRs
Number of subjects: 112
Study 8039040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of salbutamol (0.5 mg)
Number of subjects: 34
Study 8039040 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization of salbutamol (10 mg)
Number of subjects: 34
Study 8039040 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (i.v. and nebulization)
Number of subjects: 34
Study 2663010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 60
Study 2663010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2663010 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative period
Number of subjects: 60
Study 4199744 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 0
Study 31748253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting
Number of subjects: 618
Study 31748253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 618